Abstract
Small ubiquitin-like modifier (SUMO) is a family of proteins structurally similar to ubiquitin that have been found to be covalently attached to certain lysine residues of specific target proteins. By contrast to ubiquitination, however, SUMO proteins do not promote protein degradation but, instead, modulate important functional properties, depending on the protein substrate. These properties include—albeit not limited to—subcellular localization, protein dimerization, DNA binding and/or transactivation of transcription factors, among them estrogen receptors. Moreover, it has been suggested that SUMO proteins might affect transcriptional co-factor complexes of the estrogen receptor signalling cascade. Tissue and/or state specificity seems to be one of their intriguing features. In this regard, elucidation of their contribution to estrogen receptor-mediated transcriptional activity during breast carcinogenesis will offer new insights into the molecular mechanisms governing sensitivity/resistance in currently applied endocrine treatment and/or chemoprevention, and provide novel routes to breast carcinoma therapeutics.
Similar content being viewed by others
Abbreviations
- AIs:
-
Aromatase inhibitors
- AP-1:
-
Activator protein-1
- AR:
-
Androgen receptor
- C/EBP:
-
CAAT enhancer-binding protein
- EGFR:
-
Epidermal growth factor receptor
- GR:
-
Glucocorticoid receptor
- HECT:
-
Homologous to E6–AP C-terminus
- HSF:
-
Heat shock transcription factor
- Hsp:
-
Heat shock protein
- ILGF-1R:
-
Insulin like growth factor-1 receptor
- JNK:
-
c-Jun N-terminal kinase
- MAPK:
-
Mitogen-activated protein kinase
- PCNA:
-
Proliferating cell nuclear antigen
- PKA:
-
Protein kinase A
- PPARγ :
-
Peroxisome proliferator-activated receptor γ
- PR:
-
Progesterone receptor
- RXRα :
-
Rexinoid receptor α
- SREBPs:
-
Sterol regulatory element-binding proteins
- TF:
-
Transcription factor
- TK:
-
Tyrosine kinase
References
Yager JD, Davidson NE (2006) Estrogen carcinogenesis in breast cancer. N Engl J Med 354:270–282
Goldhirsch A, Glick JH, Gelber RD et al (2005) Meeting highlights: international expert consensus on the primary therapy of early breast cancer 2005. Ann Oncol 16:1569–1583
Dutertre M, Smith CL (2003) Ligand-independent interactions of p160/steroid receptor coactivators and CREB-binding protein (CBP) with estrogen receptor-alpha: regulation by phosphorylation sites in the A/B region depends on other receptor domains. Mol Endocrinol 17:1296–1314
Heldring N, Nilsson M, Buehrer B et al (2004) Identification of tamoxifen-induced coregulator interaction surfaces within the ligand-binding domain of estrogen receptors. Mol Cell Biol 24:3445–3459
Delaunay F, Pettersson K, Tujague M, Gustafsson JA (2000) Functional differences between the amino-terminal domains of estrogen receptors alpha and beta. Mol Pharmacol 58:584–590
Frasor J, Chang EC, Komm B et al (2006) Gene expression preferentially regulated by tamoxifen in breast cancer cells and correlations with clinical outcome. Cancer Res 66:7334–7340
Ruff M, Gangloff M, Wurtz JM, Moras D (2000) Estrogen receptor transcription and transactivation: structure-function relationship in DNA- and ligand-binding domains of estrogen receptors. Breast Cancer Res 2:353–359
Wang Z, Zhang X, Shen P et al (2006) A variant of estrogen receptor-{alpha}, hER-{alpha}36: transduction of estrogen- and antiestrogen-dependent membrane-initiated mitogenic signaling. Proc Natl Acad Sci USA 103:9063–9068
Leung YK, Mak P, Hassan S, Ho SM (2006) Estrogen receptor (ER)-beta isoforms: a key to understanding ER-beta signaling. Proc Natl Acad Sci USA 103:13162–13167
Karamouzis MV, Papavassiliou AG (2006) The IGF-1 network in lung carcinoma therapeutics. Trends Mol Med 12:595–602
Levin ER (2005) Integration of the extranuclear and nuclear actions of estrogen. Mol Endocrinol 19:1951–1959
Wang RA, Mazumdar A, Vadlamudi RK, Kumar R (2002) P21-activated kinase-1 phosphorylates and transactivates estrogen receptor-alpha and promotes hyperplasia in mammary epithelium. EMBO J 21:5437–5447
Song RX, Santen RJ (2006) Membrane initiated estrogen signaling in breast cancer. Biol Reprod 75:9–16
Gururaj AE, Rayala SK, Vadlamudi RK, Kumar R (2006) Novel mechanisms of resistance to endocrine therapy: genomic and nongenomic considerations. Clin Cancer Res 12:1001s–1007s
Carroll JS, Brown M (2006) Estrogen receptor target gene: an evolving concept. Mol Endocrinol 20:1707–1714
Deroo BJ, Korach KS (2006) Estrogen receptors and human disease. J Clin Invest 116:561–570
Labhart P, Karmakar S, Salicru EM et al (2005) Identification of target genes in breast cancer cells directly regulated by the SRC-3/AIB1 coactivator. Proc Natl Acad Sci USA 102:1339–1344
Rosenfeld MG, Lunyak VV, Glass CK (2006) Sensors and signals: a coactivator/corepressor/epigenetic code for integrating signal-dependent programs of transcriptional response. Genes Dev 20:1405–1428
den Hollander P, Rayala SK, Coverley D, Kumar R (2006) Ciz1, a novel DNA-binding coactivator of the estrogen receptor {alpha}, confers hypersensitivity to estrogen action. Cancer Res 66:11021–11029
Belandia B, Orford RL, Hurst HC, Parker MG (2002) Targeting of SWI/SNF chromatin remodelling complexes to estrogen-responsive genes. EMBO J 21:4094–4103
Mo R, Rao SM, Zhu YJ (2006) Identification of the MLL2 complex as a coactivator for estrogen receptor alpha. J Biol Chem 281:15714–15720
Kim JH, Li H, Stallcup MR (2003) CoCoA, a nuclear receptor coactivator which acts through an N-terminal activation domain of p160 coactivators. Mol Cell 12:1537–1549
Zhou D, Ye JJ, Li Y et al (2006) The molecular basis of the interaction between the proline-rich SH3-binding motif of PNRC and estrogen receptor alpha. Nucleic Acids Res 34:5974–5986
Lee YH, Coonrod SA, Kraus WL et al (2005) Regulation of coactivator complex assembly and function by protein arginine methylation and demethylimination. Proc Natl Acad Sci USA 102:3611–3616
Kobayashi Y, Kitamoto T, Masuhiro Y et al (2000) p300 mediates functional synergism between AF-1 and AF-2 of estrogen receptor alpha and beta by interacting directly with the N-terminal A/B domains. J Biol Chem 275:15645–15651
Webb P, Nguyen P, Shinsako J et al (1998) Estrogen receptor activation function 1 works by binding p160 coactivator proteins. Mol Endocrinol 12:1605–1618
Ding L, Yan J, Zhu J et al (2003) Ligand-independent activation of estrogen receptor alpha by XBP-1. Nucleic Acids Res 31:5266–5274
Faulds MH, Pettersson K, Gustafsson JA, Haldosen LA (2001) Cross-talk between ERs and signal transducer and activator of transcription 5 is E2 dependent and involves two functionally separate mechanisms. Mol Endocrinol 15:1929–1940
Klinge CM, Jernigan SC, Mattingly KA et al (2004) Estrogen response element-dependent regulation of transcriptional activation of estrogen receptors alpha and beta by coactivators and corepressors. J Mol Endocrinol 33:387–410
Dobrzycka KM, Townson SM, Jiang S, Oesterreich S (2003) Estrogen receptor corepressors – a role in human breast cancer? Endocr Relat Cancer 10:517–536
Shang Y, Brown M (2002) Molecular determinants for the tissue specificity of SERMs. Science 295:2465–2468
Norris JD, Fan D, Sherk A, McDonnell DP (2002) A negative coregulator for the human ER. Mol Endocrinol 16:459–468
Frasor J, Danes JM, Komm B et al (2003) Profiling of estrogen up- and down-regulated gene expression in human breast cancer cells: insights into gene networks and pathways underlying estrogenic control of proliferation and cell phenotype. Endocrinology 144:4562–4574
Augereau P, Badia E, Balaguer P et al (2006) Negative regulation of hormone signaling by RIP140. J Steroid Biochem Mol Biol 102:51–59
Fernandes I, Bastien Y, Wai T et al (2003) Ligand-dependent nuclear receptor corepressor LCoR functions by histone deacetylase-dependent and -independent mechanisms. Mol Cell 11:139–150
Shi Y, Sawada J, Sui G et al (2003) Coordinated histone modifications mediated by a CtBP co-repressor complex. Nature 422:735–738
Leader JE, Wang C, Fu M, Pestell RG (2006): Epigenetic regulation of nuclear steroid receptors. Biochem Pharmacol 72:1589–1596
Loven MA, Muster N, Yates JR, Nardulli AM (2003) A novel estrogen receptor alpha-associated protein, template-activating factor Ibeta, inhibits acetylation and transactivation. Mol Endocrinol 17:67–78
Lopez-Garcia J, Periyasamy M, Thomas RS et al (2006) ZNF366 is an estrogen receptor corepressor that acts through CtBP and histone deacetylases. Nucleic Acids Res 34:6126–6136
Lannigan DA (2003) Estrogen receptor phosphorylation. Steroids 68:1–9
Gburcik V, Bot N, Maggiolini M, Picard D (2005) SPBP is a phosphoserine-specific repressor of estrogen receptor alpha. Mol Cell Biol 25:3421–3430
Venkitaraman AR (2002) Cancer susceptibility and the functions of BRCA1 and BRCA2. Cell 108:171–182
Cui Y, Niu A, Pestell R (2006) Metastasis-associated protein 2 is a repressor of estrogen receptor alpha whose overexpression leads to estrogen-independent growth of human breast cancer cells. Mol Endocrinol 20:2020–2035
Jiang S, Meyer R, Kang K et al (2006) Scaffold attachment factor SAFB1 suppresses estrogen receptor alpha-mediated transcription in part via interaction with nuclear receptor corepressor. Mol Endocrinol 20:311–320
Townson SM, Dobrzycka KM, Lee AV et al (2003) SAFB2, a new scaffold attachment factor homolog and estrogen receptor corepressor. J Biol Chem 278:20059–20068
Wong CW, McNally C, Nickbarg E et al (2002) Estrogen receptor-interacting protein that modulates its nongenomic activity-crosstalk with Src/Erk phosphorylation cascade. Proc Natl Acad Sci USA 99:14783–14788
Karamouzis MV, Gorgoulis VG, Papavassiliou AG (2002) Transcription factors and neoplasia: vistas in novel drug design. Clin Cancer Res 8:949–961
Kinyamu HK, Chen J, Archer TK (2005) Linking the ubiquitin-proteasome pathway to chromatin remodeling/modification by nuclear receptors. J Mol Endocrinol 34:281–297
Welchman RL, Gordon C, Mayer RJ (2005) Ubiquitin and ubiquitin-like proteins as multifunctional signals. Nat Rev Mol Cell Biol 6:599–609
Tanaka K, Nishide J, Okazaki K et al (1999) Characterization of a fission yeast SUMO-1 homologue, pmt3p, required for multiple nuclear events, including the control of telomere length and chromosome segregation. Mol Cell Biol 19:8660–8672
Boddy MN, Howe K, Etkin LD et al (1996) PIC 1, a novel ubiquitin-like protein which interacts with the PML component of a multiprotein complex that is disrupted in acute promyelocytic leukaemia. Oncogene 13:971–982
Okura T, Gong L, Kamitani T et al (1996) Protection against Fas/APO-1- and tumor necrosis factor-mediated cell death by a novel protein, sentrin. J Immunol 157:4277–4281
Ulrich HD (2005) Mutual interactions between the SUMO and ubiquitin systems: a plea of no contest. Trends Cell Biol 15:525–532
Konstantinopoulos PA, Papavassiliou AG (2006) The potential of proteasome inhibition in the treatment of colon cancer. Expert Opin Investig Drugs 15:1067–1075
Hay RT (2005) SUMO: a history of modification. Mol Cell 18:1–12
Seeler JS, Dejean A (2003) Nuclear and unclear functions of SUMO. Nat Rev Mol Cell Biol 4:690–699
Gocke CB, Yu H, Kang J (2005) Systematic identification and analysis of mammalian small ubiquitin-like modifier substrates. J Biol Chem 280:5004–5012
Kamitani T, Nguyen HP, Yeh ET (1997) Preferential modification of nuclear proteins by a novel ubiquitin-like molecule. J Biol Chem 272:14001–14004
Johnson ES, Schwienhorst I, Dohmen RJ, Blobel G (1997) The ubiquitin-like protein Smt3p is activated for conjugation to other proteins by an Aos1p/Uba2p heterodimer. EMBO J 16:5509–5519
Gong L, Kamitani T, Fujise K et al (1997) Preferential interaction of sentrin with a ubiquitin-conjugating enzyme, Ubc9. J Biol Chem 272:28198–28201
Johnson ES, Blobel G (1997) Ubc9p is the conjugating enzyme for the ubiquitin-like protein Smt3p. J Biol Chem 272:26799–26802
Kamitani T, Nguyen HP, Kito K et al (1998) Covalent modification of PML by the sentrin family of ubiquitin-like proteins. J Biol Chem 273:3117–3120
Tatham MH, Chen Y, Hay RT (2003) Role of two residues proximal to the active site of Ubc9 in substrate recognition by the Ubc9 SUMO-1 thiolester complex. Biochemistry 42:3168–3179
Liu B, Mink S, Wong KA et al (2004) PIAS1 selectively inhibits interferon-inducible genes and is important in innate immunity. Nat Immunol 5:891–898
Pichler A, Gast A, Seeler JS et al (2002) The nucleoporin RanBP2 has SUMO1 E3 ligase activity. Cell 108:109–120
Kagey MH, Melhuish TA, Wotton D (2003) The polycomb protein Pc2 is a SUMO E3. Cell 113:127–137
Schwartz DC, Hochstrasser M (2003) A superfamily of protein tags: ubiquitin, SUMO and related modifiers. Trends Biochem Sci 28:321–328
Hochstrasser M (2001) SP-RING for SUMO: new functions bloom for a ubiquitin-like protein. Cell 107:5–8
Schmidt D, Muller S (2003) PIAS/SUMO: new partners in transcriptional regulation. Cell Mol Life Sci 60:2561–2574
Sharrocks AD (2006) PIAS proteins and transcriptional regulation–more than just SUMO E3 ligases? Genes Dev 20:754–758
Reverter D, Lima CD (2005) Insights into E3 ligase activity revealed by a SUMO-RanGAP1-Ubc9-Nup358 complex. Nature 435:687–692
Alarcon-Vargas D, Ronai Z (2002) SUMO in cancer–wrestlers wanted. Cancer Biol Ther 1:237–242
Kamitani T, Kito K, Nguyen HP et al (1998) Characterization of a second member of the sentrin family of ubiquitin-like proteins. J Biol Chem 273:11349–11359
Saitoh H, Hinchey J (2000) Functional heterogeneity of small ubiquitin-related protein modifiers SUMO-1 versus SUMO-2/3. J Biol Chem 275:6252–6258
Tatham MH, Jaffray E, Vaughan OA et al (2001) Polymeric chains of SUMO-2 and SUMO-3 are conjugated to protein substrates by SAE1/SAE2 and Ubc9. J Biol Chem 276:35368–35374
Owerbach D, McKay EM, Yeh ET et al (2005) A proline-90 residue unique to SUMO-4 prevents maturation and sumoylation. Biochem Biophys Res Commun 337:517–520
Cheng J, Bawa T, Lee P et al. (2006) Role of desumoylation in the development of prostate cancer. Neoplasia 8:667–676
Gong L, Millas S, Maul GG, Yeh ET (2000) Differential regulation of sentrinized proteins by a novel sentrin-specific protease. J Biol Chem 275:3355–3359
Bailey D, O’Hare P (2004) Characterization of the localization and proteolytic activity of the SUMO-specific protease, SENP1. J Biol Chem 279:692–703
Hang J, Dasso M (2002) Association of the human SUMO-1 protease SENP2 with the nuclear pore. J Biol Chem 277:19961–19966
Zhang H, Saitoh H, Matunis MJ (2002) Enzymes of the SUMO modification pathway localize to filaments of the nuclear pore complex. Mol Cell Biol 22:6498–6508
Best JL, Ganiatsas S, Agarwal S et al (2001) SUMO-1 protease-1 regulates gene transcription through PML. Mol Cell 10:843–855
Nishida T, Kaneko F, Kitagawa M, Yasuda H (2001) Characterization of a novel mammalian SUMO-1/Smt3-specific isopeptidase, a homologue of rat axam, which is an axin-binding protein promoting beta-catenin degradation. J Biol Chem 276:39060–39066
Nishida T, Tanaka H, Yasuda H (2000) A novel mammalian Smt3-specific isopeptidase 1 (SMT3IP1) localized in the nucleolus at interphase. Eur J Biochem 267:6423–6427
Faus H, Haendler B (2006) Post-translational modifications of steroid receptors. Biomed Pharmacother 60:520–528
Gong L, Yeh ET (2006) Characterization of a family of nucleolar SUMO-specific proteases with preference for SUMO-2 or SUMO-3. J Biol Chem 281:15869–15877
Johnson ES (2004) Protein modification by SUMO. Annu Rev Biochem 73:355–382
Muller S, Ledl A, Schmidt D (2004) SUMO: a regulator of gene expression and genome integrity. Oncogene 23:1998–2008
Christians ES, Zhou Q, Renard J, Benjamin IJ (2003) Heat shock proteins in mammalian development. Semin Cell Dev Biol 14:283–290
Shuai K, Liu B (2005) Regulation of gene-activation pathways by PIAS proteins in the immune system. Nat Rev Immunol 5:593–605
Chauchereau A, Amazit L, Quesne M et al (2003) Sumoylation of the progesterone receptor and of the steroid receptor coactivator SRC-1. J Biol Chem 278:12335–12343
Gill G (2004) SUMO and ubiquitin in the nucleus: different functions, similar mechanisms? Genes Dev 18:2046–2059
Poukka H, Karvonen U, Janne OA, Palvimo JJ (2000) Covalent modification of the androgen receptor by small ubiquitin-like modifier 1 (SUMO-1). Proc Natl Acad Sci USA 97:14145–14150
Abdel-Hafiz H, Takimoto GS, Tung L, Horwitz KB (2002) The inhibitory function in human progesterone receptor N termini binds SUMO-1 protein to regulate autoinhibition and transrepression. J Biol Chem 277:33950–33956
Le Drean Y, Mincheneau N, Le Goff P, Michel D (2002) Potentiation of glucocorticoid receptor transcriptional activity by sumoylation. Endocrinology 143:3482–3489
Ohshima T, Koga H, Shimotohno K (2004) Transcriptional activity of peroxisome proliferator-activated receptor gamma is modulated by SUMO-1 modification. J Biol Chem 279:29551–29557
Choi SJ, Chung SS, Rho EJ et al (2006) Negative modulation of RXRalpha transcriptional activity by small ubiquitin-related modifier (SUMO) modification and its reversal by SUMO-specific protease SUSP1. J Biol Chem 281:30669–30677
Desterro JM, Rodriguez MS, Hay RT (1998) SUMO-1 modification of IkappaBalpha inhibits NF-kappaB activation. Mol Cell 2:233–239
Ji Z, Degerny C, Vintonenko N et al (2007) Regulation of the Ets-1 transcription factor by sumoylation and ubiquitinylation. Oncogene 26:395–406
Iniguez-Lluhi JA, Pearce D (2000) A common motif within the negative regulatory regions of multiple factors inhibits their transcriptional synergy. Mol Cell Biol 20:6040–6050
Kagey MH, Melhuish TA, Powers SE, Wotton D (2005) Multiple activities contribute to Pc2 E3 function. EMBO J 24:108–119
David G, Neptune MA, DePinho RA (2002) SUMO-1 modification of histone deacetylase 1 (HDAC1) modulates its biological activities. J Biol Chem 277:23658–23663
Girdwood D, Bumpass D, Vaughan OA et al (2003) P300 transcriptional repression is mediated by SUMO modification. Mol Cell 11:1043–1054
Kirsh O, Seeler JS, Pichler A et al (2002) The SUMO E3 ligase RanBP2 promotes modification of the HDAC4 deacetylase. EMBO J 21:2682–2691
Yang SH, Sharrocks AD (2004) SUMO promotes HDAC-mediated transcriptional repression. Mol Cell 13:611–617
Konstantinopoulos PA, Papavassiliou AG (2006) Chromatin-modulating agents as epigenetic anticancer drugs–‘the die is cast’. Drug Discov Today 11:91–93
Shiio Y, Eisenman RN (2003) Histone sumoylation is associated with transcriptional repression. Proc Natl Acad Sci USA 100:13225–13230
Ling Y, Sankpal UT, Robertson AK et al (2004) Modification of de novo DNA methyltransferase 3a (Dnmt3a) by SUMO-1 modulates its interaction with histone deacetylases (HDACs) and its capacity to repress transcription. Nucleic Acids Res 32:598–610
Bossis G, Melchior F (2006) SUMO: regulating the regulator. Cell Div 1:13
Galy A, Neron B, Planque N et al (2002) Activated MAPK/ERK kinase (MEK-1) induces transdifferentiation of pigmented epithelium into neural retina. Dev Biol 248:251–264
Wood LD, Irvin BJ, Nucifora G et al (2003) Small ubiquitin-like modifier conjugation regulates nuclear export of TEL, a putative tumor suppressor. Proc Natl Acad Sci USA 100:3257–3262
Kwek SS, Derry J, Tyner AL et al (2001) Functional analysis and intracellular localization of p53 modified by SUMO-1. Oncogene 20:2587–2599
Schmidt D, Muller S (2002) Members of the PIAS family act as SUMO ligases for c-Jun and p53 and repress p53 activity. Proc Natl Acad Sci USA 99:2872–2877
Cheng J, Perkins ND, Yeh ET (2005) Differential regulation of c-Jun-dependent transcription by SUMO-specific proteases. J Biol Chem 280:14492–14498
Hoeller D, Hecker CM, Dikic I (2006) Ubiquitin and ubiquitin-like proteins in cancer pathogenesis. Nat Rev Cancer 6:776–788
Baek SH (2006) A novel link between SUMO modification and cancer metastasis. Cell Cycle 5:1492–1495
Kim JH, Choi HJ, Kim B et al (2006) Roles of sumoylation of a reptin chromatin-remodelling complex in cancer metastasis. Nat Cell Biol 8:631–639
Singh RR, Kumar R (2005) Steroid hormone receptor signaling in tumorigenesis. J Cell Biochem 96:490–505
Chen D, Pace PE, Coombes RC, Ali S (1999) Phosphorylation of human estrogen receptor alpha by protein kinase A regulates dimerization. Mol Cell Biol 19:1002–1015
Sentis S, Le Romancer M, Bianchin C et al (2005) Sumoylation of the estrogen receptor alpha hinge region regulates its transcriptional activity. Mol Endocrinol 19:2671–2684
Wang L, Banerjee S (2004) Differential PIAS3 expression in human malignancy. Oncol Rep 11:1319–1324
Fuqua SA, Wiltschke C, Zhang QX et al (2000) A hypersensitive estrogen receptor-alpha mutation in premalignant breast lesions. Cancer Res 60:4026–4029
Zhang H, Yi X, Sun X et al (2004) Differential gene regulation by the SRC family of coactivators. Genes Dev 18:1753–1765
Wu RC, Qin J, Yi P et al (2004) Selective phosphorylations of the SRC-3/AIB1 coactivator integrate genomic reponses to multiple cellular signaling pathways. Mol Cell 15:937–949
Torres-Arzayus MI, Font de Mora J, Yuan J et al (2004) High tumor incidence and activation of the PI3K/AKT pathway in transgenic mice define AIB1 as an oncogene. Cancer Cell 6:263–274
Rowan BG, Weigel NL, O’Malley BW (2000) Phosphorylation of steroid receptor coactivator-1. Identification of the phosphorylation sites and phosphorylation through the mitogen-activated protein kinase pathway. J Biol Chem 275:4475–4483
Lopez GN, Turck CW, Schaufele F et al (2001) Growth factors signal to steroid receptors through mitogen-activated protein kinase regulation of p160 coactivator activity. J Biol Chem 276:22177–22182
Font de Mora J, Brown M (2000) AIB1 is a conduit for kinase-mediated growth factor signaling to the estrogen receptor. Mol Cell Biol 20:5041–5047
Kotaja N, Karvonen U, Janne OA, Palvimo JJ (2002) The nuclear receptor interaction domain of GRIP1 is modulated by covalent attachment of SUMO-1. J Biol Chem 277:30283–30288
Wu H, Sun L, Zhang Y et al (2006) Coordinated regulation of AIB1 transcriptional activity by sumoylation and phosphorylation. J Biol Chem 281:21848–21856
Karamouzis MV, Papadas T, Varakis I et al (2002) Induction of the CBP transcriptional co-activator early during laryngeal carcinogenesis. J Cancer Res Clin Oncol 128:135–140
Kuo HY, Chang CC, Jeng JC et al (2005) SUMO modification negatively modulates the transcriptional activity of CREB-binding protein via the recruitment of Daxx. Proc Natl Acad Sci USA 102:16973–16978
Tiefenbach J, Novac N, Ducasse M et al (2006) SUMOylation of the corepressor N-CoR modulates its capacity to repress transcription. Mol Biol Cell 17:1643–1651
Lu Z, Wu H, Mo YY (2006) Regulation of bcl-2 expression by Ubc9. Exp Cell Res 312:1865–1875
Tremblay A, Tremblay GB, Labrie F, Giguere V (1999) Ligand-independent recruitment of SRC-1 to estrogen receptor beta through phosphorylation of activation function AF-1. Mol Cell 3:513–519
Bjornstrom L, Sjoberg M (2004) Estrogen receptor-dependent activation of AP-1 via non-genomic signalling. Nucl Recept 2:3
Cheung E, Acevedo ML, Cole PA, Kraus WL (2005) Altered pharmacology and distinct coactivator usage for estrogen receptor-dependent transcription through activating protein-1. Proc Natl Acad Sci USA 102:559–564
Lin X, Sun B, Liang M et al (2003) Opposed regulation of corepressor CtBP by SUMOylation and PDZ binding. Mol Cell 11:1389–1396
Sobko A, Ma H, Firtel RA (2002) Regulated SUMOylation and ubiquitination of DdMEK1 is required for proper chemotaxis. Dev Cell 2:745–756
Normanno N, Di Maio M, De Maio E et al (2005) Mechanisms of endocrine resistance and novel therapeutic strategies in breast cancer. Endocr Relat Cancer 12:721–747
Lewis JS, Jordan VC (2005) Selective estrogen receptor modulators (SERMs): mechanisms of anticarcinogenesis and drug resistance. Mutat Res 591:247–263
Ring A, Dowsett M (2004) Mechanisms of tamoxifen resistance. Endocr Relat Cancer 11:643–658
Osborne CK, Bardou V, Hopp TA et al (2003) Role of the estrogen receptor coactivator AIB1 (SRC-3) and HER-2/neu in tamoxifen resistance in breast cancer. J Natl Cancer Inst 95:353–361
Anzick SL, Kononen J, Walker RL et al (1997) AIB1, a steroid receptor coactivator amplified in breast and ovarian cancer. Science 277:965–968
Yang SH, Jaffray E, Hay RT, Sharrocks AD (2003) Dynamic interplay of the SUMO and ERK pathways in regulating Elk-1 transcriptional activity. Mol Cell 12:63–74
Jepsen K, Hermanson O, Onami TM et al (2000) Combinatorial roles of the nuclear receptor corepressor in transcription and development. Cell 102:753–763
Nicholson RI, Hutcheson IR, Knowlden JM et al (2004) Non endocrine pathways and endocrine resistance: observations with antiestrogens and signal transduction inhibitors in combination. Clin Cancer Res 10:346S–354S
Bruggemeier RW (2006) Update on the use of aromatase inhibitors in breast cancer. Expert Opin Pharmacother 7:1919–1930
Dowsett M, Martin LA, Smith I, Johnston S (2005) Mechanisms of resistance to aromatase inhibitors. J Steroid Biochem Mol Biol 95:167–172
Choi JY, Nowell SA, Blanco JG, Ambrosone CB (2006) The role of genetic variability in drug metabolism pathways in breast cancer prognosis. Pharmacogenomics 7:613–624
Martin LA, Farmer I, Johnston SR et al (2003) Enhanced estrogen receptor (ER) alpha, ERBB2, and MAPK signal transduction pathways operate during the adaptation of MCF-7 cells to long term estrogen deprivation. J Biol Chem 278:30458–30468
Brodie A, Jelovac D, Macedo L et al (2005) Therapeutic observations in MCF-7 aromatase xenografts. Clin Cancer Res 11:884s–888s
Teyssier C, Belguise K, Galtier F, Chalbos D (2001) Characterization of the physical interaction between estrogen receptor alpha and JUN proteins. J Biol Chem 276:36361–36369
Bossis G, Malnou CE, Farras R et al (2005) Down-regulation of c-Fos/c-Jun AP-1 dimer activity by sumoylation. Mol Cell Biol 25:6964–6979
Mo YY, Moschos SJ (2005) Targeting Ubc9 for cancer therapy. Expert Opin Ther Targets 9:1203–1216
Jacquiau HR, van Waardenburg RC et al (2005) Defects in SUMO (small ubiquitin-related modifier) conjugation and deconjugation alter cell sensitivity to DNA topoisomerase I-induced DNA damage. J Biol Chem 280:23566–23575
Johnston SR (2005) Combinations of endocrine and biological agents: present status of therapeutic and presurgical investigations. Clin Cancer Res 11:889s–899s
Adams J (2004) The development of proteasome inhibitors as anticancer drugs. Cancer Cell 5:417–421
Boggio R, Colombo R, Hay RT et al (2004) A mechanism for inhibiting the SUMO pathway. Mol Cell 16:549–561
Author information
Authors and Affiliations
Corresponding author
Rights and permissions
About this article
Cite this article
Karamouzis, M.V., Konstantinopoulos, P.A., Badra, F.A. et al. SUMO and estrogen receptors in breast cancer. Breast Cancer Res Treat 107, 195–210 (2008). https://doi.org/10.1007/s10549-007-9552-5
Received:
Accepted:
Published:
Issue Date:
DOI: https://doi.org/10.1007/s10549-007-9552-5